Zyprexa Zydis

Delirium, Delusional Parasitosis, Schizophrenia + 11 more

Treatment

8 FDA approvals

20 Active Studies for Zyprexa Zydis

What is Zyprexa Zydis

Olanzapine

The Generic name of this drug

Treatment Summary

Olanzapine is an atypical antipsychotic medication used to treat mental health conditions. It was introduced in the 1990s and is known for its effectiveness, reduced risk of side effects and low chance of drug-drug interactions. Olanzapine is similar to clozapine but has two additional methyl groups and no chloride moiety. It was approved by the FDA and released in the US in 1996.

Zyprexa

is the brand name

image of different drug pills on a surface

Zyprexa Zydis Overview & Background

Brand Name

Generic Name

First FDA Approval

How many FDA approvals?

Zyprexa

Olanzapine

1996

546

Approved as Treatment by the FDA

Olanzapine, otherwise known as Zyprexa, is approved by the FDA for 8 uses which include Mental Depression and Bipolar Disorder .

Mental Depression

Used to treat Acute Depressive Episode in combination with Fluoxetine

Bipolar Disorder

Used to treat Bipolar 1 Disorder in combination with Fluoxetine

Bipolar Disorder

Used to treat Bipolar Disorder With Manic or Mixed Episodes in combination with Lithium cation

Unipolar Depression

Used to treat Major depressive disorder, recurrent episode in combination with Fluoxetine

Bipolar Disorder With Manic or Mixed Episodes

Used to treat Bipolar Disorder With Manic or Mixed Episodes in combination with Lithium cation

Bipolar 1 Disorder

Used to treat Bipolar 1 Disorder in combination with Fluoxetine

Acute Depressive Episode

Used to treat Acute Depressive Episode in combination with Fluoxetine

Major depressive disorder, recurrent episode

Used to treat Major depressive disorder, recurrent episode in combination with Fluoxetine

Effectiveness

How Zyprexa Zydis Affects Patients

Olanzapine works by targeting the dopamine D2 receptor and the serotonin 5HT2A receptor in the body. This helps to decrease hallucinations, delusions, disorganized speech, disorganized thought, and disorganized behavior, as well as improve feelings of sadness, lack of energy, lack of interest in activities, difficulty making decisions, and poor attention. Olanzapine has been shown to be effective in treating schizophrenia and bipolar disorder in adults and reducing manic or mixed episodes in adolescents. It has also been studied for its ability to reduce nausea and vomiting caused by chemotherapy, with studies showing that it can help control these symptoms in over 80

How Zyprexa Zydis works in the body

Olanzapine works by blocking receptors in the brain, including receptors for dopamine and serotonin. This blocking prevents dopamine from having an effect on the post-synaptic receptor. Olanzapine also blocks serotonin receptors in the frontal cortex, which helps reduce side effects.

When to interrupt dosage

The advised dosage of Zyprexa Zydis is contingent upon the recognized condition, such as Schizophrenia, Bipolar Disorder and Delirium. The measure of dosage fluctuates as per the method of administration (e.g. Kit - Intramuscular or Tablet, film coated - Oral) detailed in the table beneath.

Condition

Dosage

Administration

Delirium

2.5 mg, , 5.0 mg, 20.0 mg, 15.0 mg, 10.0 mg, 10.0 mg/mL, 7.5 mg, 3.0 mg, 6.0 mg, 12.0 mg, 210.0 mg, 300.0 mg, 405.0 mg, 405.0 mg/mL, 300.0 mg/mL, 210.0 mg/mL

, Oral, Tablet, film coated - Oral, Tablet, film coated, Intramuscular, Injection, powder, for solution - Intramuscular, Injection, powder, for solution, Tablet, Tablet - Oral, Capsule, Capsule - Oral, Tablet, orally disintegrating - Oral, Tablet, orally disintegrating, Injection, powder, lyophilized, for solution, Injection, powder, lyophilized, for solution - Intramuscular, Powder, for solution, Powder, for solution - Intramuscular, Tablet, coated - Oral, Tablet, coated, Injection, powder, for suspension, extended release, Injection, powder, for suspension, extended release - Intramuscular, Kit, Kit - Intramuscular

Schizophrenia

2.5 mg, , 5.0 mg, 20.0 mg, 15.0 mg, 10.0 mg, 10.0 mg/mL, 7.5 mg, 3.0 mg, 6.0 mg, 12.0 mg, 210.0 mg, 300.0 mg, 405.0 mg, 405.0 mg/mL, 300.0 mg/mL, 210.0 mg/mL

, Oral, Tablet, film coated - Oral, Tablet, film coated, Intramuscular, Injection, powder, for solution - Intramuscular, Injection, powder, for solution, Tablet, Tablet - Oral, Capsule, Capsule - Oral, Tablet, orally disintegrating - Oral, Tablet, orally disintegrating, Injection, powder, lyophilized, for solution, Injection, powder, lyophilized, for solution - Intramuscular, Powder, for solution, Powder, for solution - Intramuscular, Tablet, coated - Oral, Tablet, coated, Injection, powder, for suspension, extended release, Injection, powder, for suspension, extended release - Intramuscular, Kit, Kit - Intramuscular

Schizophrenia

2.5 mg, , 5.0 mg, 20.0 mg, 15.0 mg, 10.0 mg, 10.0 mg/mL, 7.5 mg, 3.0 mg, 6.0 mg, 12.0 mg, 210.0 mg, 300.0 mg, 405.0 mg, 405.0 mg/mL, 300.0 mg/mL, 210.0 mg/mL

, Oral, Tablet, film coated - Oral, Tablet, film coated, Intramuscular, Injection, powder, for solution - Intramuscular, Injection, powder, for solution, Tablet, Tablet - Oral, Capsule, Capsule - Oral, Tablet, orally disintegrating - Oral, Tablet, orally disintegrating, Injection, powder, lyophilized, for solution, Injection, powder, lyophilized, for solution - Intramuscular, Powder, for solution, Powder, for solution - Intramuscular, Tablet, coated - Oral, Tablet, coated, Injection, powder, for suspension, extended release, Injection, powder, for suspension, extended release - Intramuscular, Kit, Kit - Intramuscular

Bipolar Disorder

2.5 mg, , 5.0 mg, 20.0 mg, 15.0 mg, 10.0 mg, 10.0 mg/mL, 7.5 mg, 3.0 mg, 6.0 mg, 12.0 mg, 210.0 mg, 300.0 mg, 405.0 mg, 405.0 mg/mL, 300.0 mg/mL, 210.0 mg/mL

, Oral, Tablet, film coated - Oral, Tablet, film coated, Intramuscular, Injection, powder, for solution - Intramuscular, Injection, powder, for solution, Tablet, Tablet - Oral, Capsule, Capsule - Oral, Tablet, orally disintegrating - Oral, Tablet, orally disintegrating, Injection, powder, lyophilized, for solution, Injection, powder, lyophilized, for solution - Intramuscular, Powder, for solution, Powder, for solution - Intramuscular, Tablet, coated - Oral, Tablet, coated, Injection, powder, for suspension, extended release, Injection, powder, for suspension, extended release - Intramuscular, Kit, Kit - Intramuscular

Post Traumatic Stress Disorder

2.5 mg, , 5.0 mg, 20.0 mg, 15.0 mg, 10.0 mg, 10.0 mg/mL, 7.5 mg, 3.0 mg, 6.0 mg, 12.0 mg, 210.0 mg, 300.0 mg, 405.0 mg, 405.0 mg/mL, 300.0 mg/mL, 210.0 mg/mL

, Oral, Tablet, film coated - Oral, Tablet, film coated, Intramuscular, Injection, powder, for solution - Intramuscular, Injection, powder, for solution, Tablet, Tablet - Oral, Capsule, Capsule - Oral, Tablet, orally disintegrating - Oral, Tablet, orally disintegrating, Injection, powder, lyophilized, for solution, Injection, powder, lyophilized, for solution - Intramuscular, Powder, for solution, Powder, for solution - Intramuscular, Tablet, coated - Oral, Tablet, coated, Injection, powder, for suspension, extended release, Injection, powder, for suspension, extended release - Intramuscular, Kit, Kit - Intramuscular

Tourette Syndrome

2.5 mg, , 5.0 mg, 20.0 mg, 15.0 mg, 10.0 mg, 10.0 mg/mL, 7.5 mg, 3.0 mg, 6.0 mg, 12.0 mg, 210.0 mg, 300.0 mg, 405.0 mg, 405.0 mg/mL, 300.0 mg/mL, 210.0 mg/mL

, Oral, Tablet, film coated - Oral, Tablet, film coated, Intramuscular, Injection, powder, for solution - Intramuscular, Injection, powder, for solution, Tablet, Tablet - Oral, Capsule, Capsule - Oral, Tablet, orally disintegrating - Oral, Tablet, orally disintegrating, Injection, powder, lyophilized, for solution, Injection, powder, lyophilized, for solution - Intramuscular, Powder, for solution, Powder, for solution - Intramuscular, Tablet, coated - Oral, Tablet, coated, Injection, powder, for suspension, extended release, Injection, powder, for suspension, extended release - Intramuscular, Kit, Kit - Intramuscular

Mental Depression

2.5 mg, , 5.0 mg, 20.0 mg, 15.0 mg, 10.0 mg, 10.0 mg/mL, 7.5 mg, 3.0 mg, 6.0 mg, 12.0 mg, 210.0 mg, 300.0 mg, 405.0 mg, 405.0 mg/mL, 300.0 mg/mL, 210.0 mg/mL

, Oral, Tablet, film coated - Oral, Tablet, film coated, Intramuscular, Injection, powder, for solution - Intramuscular, Injection, powder, for solution, Tablet, Tablet - Oral, Capsule, Capsule - Oral, Tablet, orally disintegrating - Oral, Tablet, orally disintegrating, Injection, powder, lyophilized, for solution, Injection, powder, lyophilized, for solution - Intramuscular, Powder, for solution, Powder, for solution - Intramuscular, Tablet, coated - Oral, Tablet, coated, Injection, powder, for suspension, extended release, Injection, powder, for suspension, extended release - Intramuscular, Kit, Kit - Intramuscular

Acute Agitation

2.5 mg, , 5.0 mg, 20.0 mg, 15.0 mg, 10.0 mg, 10.0 mg/mL, 7.5 mg, 3.0 mg, 6.0 mg, 12.0 mg, 210.0 mg, 300.0 mg, 405.0 mg, 405.0 mg/mL, 300.0 mg/mL, 210.0 mg/mL

, Oral, Tablet, film coated - Oral, Tablet, film coated, Intramuscular, Injection, powder, for solution - Intramuscular, Injection, powder, for solution, Tablet, Tablet - Oral, Capsule, Capsule - Oral, Tablet, orally disintegrating - Oral, Tablet, orally disintegrating, Injection, powder, lyophilized, for solution, Injection, powder, lyophilized, for solution - Intramuscular, Powder, for solution, Powder, for solution - Intramuscular, Tablet, coated - Oral, Tablet, coated, Injection, powder, for suspension, extended release, Injection, powder, for suspension, extended release - Intramuscular, Kit, Kit - Intramuscular

Unipolar Depression

2.5 mg, , 5.0 mg, 20.0 mg, 15.0 mg, 10.0 mg, 10.0 mg/mL, 7.5 mg, 3.0 mg, 6.0 mg, 12.0 mg, 210.0 mg, 300.0 mg, 405.0 mg, 405.0 mg/mL, 300.0 mg/mL, 210.0 mg/mL

, Oral, Tablet, film coated - Oral, Tablet, film coated, Intramuscular, Injection, powder, for solution - Intramuscular, Injection, powder, for solution, Tablet, Tablet - Oral, Capsule, Capsule - Oral, Tablet, orally disintegrating - Oral, Tablet, orally disintegrating, Injection, powder, lyophilized, for solution, Injection, powder, lyophilized, for solution - Intramuscular, Powder, for solution, Powder, for solution - Intramuscular, Tablet, coated - Oral, Tablet, coated, Injection, powder, for suspension, extended release, Injection, powder, for suspension, extended release - Intramuscular, Kit, Kit - Intramuscular

Acute Coryza

2.5 mg, , 5.0 mg, 20.0 mg, 15.0 mg, 10.0 mg, 10.0 mg/mL, 7.5 mg, 3.0 mg, 6.0 mg, 12.0 mg, 210.0 mg, 300.0 mg, 405.0 mg, 405.0 mg/mL, 300.0 mg/mL, 210.0 mg/mL

, Oral, Tablet, film coated - Oral, Tablet, film coated, Intramuscular, Injection, powder, for solution - Intramuscular, Injection, powder, for solution, Tablet, Tablet - Oral, Capsule, Capsule - Oral, Tablet, orally disintegrating - Oral, Tablet, orally disintegrating, Injection, powder, lyophilized, for solution, Injection, powder, lyophilized, for solution - Intramuscular, Powder, for solution, Powder, for solution - Intramuscular, Tablet, coated - Oral, Tablet, coated, Injection, powder, for suspension, extended release, Injection, powder, for suspension, extended release - Intramuscular, Kit, Kit - Intramuscular

Delusional Parasitosis

2.5 mg, , 5.0 mg, 20.0 mg, 15.0 mg, 10.0 mg, 10.0 mg/mL, 7.5 mg, 3.0 mg, 6.0 mg, 12.0 mg, 210.0 mg, 300.0 mg, 405.0 mg, 405.0 mg/mL, 300.0 mg/mL, 210.0 mg/mL

, Oral, Tablet, film coated - Oral, Tablet, film coated, Intramuscular, Injection, powder, for solution - Intramuscular, Injection, powder, for solution, Tablet, Tablet - Oral, Capsule, Capsule - Oral, Tablet, orally disintegrating - Oral, Tablet, orally disintegrating, Injection, powder, lyophilized, for solution, Injection, powder, lyophilized, for solution - Intramuscular, Powder, for solution, Powder, for solution - Intramuscular, Tablet, coated - Oral, Tablet, coated, Injection, powder, for suspension, extended release, Injection, powder, for suspension, extended release - Intramuscular, Kit, Kit - Intramuscular

Bipolar Disorder

2.5 mg, , 5.0 mg, 20.0 mg, 15.0 mg, 10.0 mg, 10.0 mg/mL, 7.5 mg, 3.0 mg, 6.0 mg, 12.0 mg, 210.0 mg, 300.0 mg, 405.0 mg, 405.0 mg/mL, 300.0 mg/mL, 210.0 mg/mL

, Oral, Tablet, film coated - Oral, Tablet, film coated, Intramuscular, Injection, powder, for solution - Intramuscular, Injection, powder, for solution, Tablet, Tablet - Oral, Capsule, Capsule - Oral, Tablet, orally disintegrating - Oral, Tablet, orally disintegrating, Injection, powder, lyophilized, for solution, Injection, powder, lyophilized, for solution - Intramuscular, Powder, for solution, Powder, for solution - Intramuscular, Tablet, coated - Oral, Tablet, coated, Injection, powder, for suspension, extended release, Injection, powder, for suspension, extended release - Intramuscular, Kit, Kit - Intramuscular

Alzheimer's Disease

2.5 mg, , 5.0 mg, 20.0 mg, 15.0 mg, 10.0 mg, 10.0 mg/mL, 7.5 mg, 3.0 mg, 6.0 mg, 12.0 mg, 210.0 mg, 300.0 mg, 405.0 mg, 405.0 mg/mL, 300.0 mg/mL, 210.0 mg/mL

, Oral, Tablet, film coated - Oral, Tablet, film coated, Intramuscular, Injection, powder, for solution - Intramuscular, Injection, powder, for solution, Tablet, Tablet - Oral, Capsule, Capsule - Oral, Tablet, orally disintegrating - Oral, Tablet, orally disintegrating, Injection, powder, lyophilized, for solution, Injection, powder, lyophilized, for solution - Intramuscular, Powder, for solution, Powder, for solution - Intramuscular, Tablet, coated - Oral, Tablet, coated, Injection, powder, for suspension, extended release, Injection, powder, for suspension, extended release - Intramuscular, Kit, Kit - Intramuscular

Bipolar Disorder

2.5 mg, , 5.0 mg, 20.0 mg, 15.0 mg, 10.0 mg, 10.0 mg/mL, 7.5 mg, 3.0 mg, 6.0 mg, 12.0 mg, 210.0 mg, 300.0 mg, 405.0 mg, 405.0 mg/mL, 300.0 mg/mL, 210.0 mg/mL

, Oral, Tablet, film coated - Oral, Tablet, film coated, Intramuscular, Injection, powder, for solution - Intramuscular, Injection, powder, for solution, Tablet, Tablet - Oral, Capsule, Capsule - Oral, Tablet, orally disintegrating - Oral, Tablet, orally disintegrating, Injection, powder, lyophilized, for solution, Injection, powder, lyophilized, for solution - Intramuscular, Powder, for solution, Powder, for solution - Intramuscular, Tablet, coated - Oral, Tablet, coated, Injection, powder, for suspension, extended release, Injection, powder, for suspension, extended release - Intramuscular, Kit, Kit - Intramuscular

Warnings

There are 20 known major drug interactions with Zyprexa Zydis.

Common Zyprexa Zydis Drug Interactions

Drug Name

Risk Level

Description

Acenocoumarol

Major

The metabolism of Acenocoumarol can be decreased when combined with Olanzapine.

Acepromazine

Major

Olanzapine may increase the orthostatic hypotensive, hypotensive, and antihypertensive activities of Acepromazine.

Aclidinium

Major

The risk or severity of adverse effects can be increased when Olanzapine is combined with Aclidinium.

Alfuzosin

Major

Olanzapine may increase the hypotensive activities of Alfuzosin.

Amisulpride

Major

Olanzapine may increase the antipsychotic activities of Amisulpride.

Zyprexa Zydis Toxicity & Overdose Risk

Taking too much olanzapine can cause drowsiness, enlarged pupils, slow or shallow breathing, low blood pressure, muscle stiffness, dry mouth, and confusion. In more severe cases, people may experience agitation, slurred speech, fast heartbeat, and reduced consciousness. In rare cases, taking too much olanzapine can even lead to death. If someone has overdosed on olanzapine, it is important to ensure they are getting enough oxygen and to give them activated charcoal with a laxative. Animal studies have linked olanzapine to an increased risk of liver tumors, mammary gland tumors

image of a doctor in a lab doing drug, clinical research

Zyprexa Zydis Novel Uses: Which Conditions Have a Clinical Trial Featuring Zyprexa Zydis?

At present, 578 active clinical trials are evaluating the potential of Zyprexa Zydis to alleviate Schizophrenia, Post Traumatic Stress Disorder and Delusional Parasitosis.

Condition

Clinical Trials

Trial Phases

Schizophrenia

83 Actively Recruiting

Phase 3, Not Applicable, Early Phase 1, Phase 4, Phase 1, Phase 2

Post Traumatic Stress Disorder

225 Actively Recruiting

Early Phase 1, Not Applicable, Phase 3, Phase 2, Phase 1, Phase 4

Bipolar Disorder

0 Actively Recruiting

Schizophrenia

33 Actively Recruiting

Early Phase 1, Not Applicable, Phase 4

Mental Depression

1 Actively Recruiting

Not Applicable

Delirium

20 Actively Recruiting

Phase 2, Phase 3, Not Applicable, Phase 4, Early Phase 1

Unipolar Depression

43 Actively Recruiting

Not Applicable, Early Phase 1, Phase 3, Phase 2, Phase 1

Bipolar Disorder

0 Actively Recruiting

Bipolar Disorder

0 Actively Recruiting

Delusional Parasitosis

0 Actively Recruiting

Alzheimer's Disease

34 Actively Recruiting

Phase 4, Phase 2, Phase 3, Phase 1, Not Applicable

Acute Coryza

0 Actively Recruiting

Acute Agitation

0 Actively Recruiting

Tourette Syndrome

0 Actively Recruiting

Zyprexa Zydis Reviews: What are patients saying about Zyprexa Zydis?

5

Patient Review

2/18/2012

Zyprexa Zydis for Additional Medications to Treat Depression

Zydis has really helped me. I've experienced an increase in appetite and weight gain, but it's worth it for the relief it provides.

5

Patient Review

7/19/2009

Zyprexa Zydis for Additional Medications to Treat Depression

I found this medication to be really great. I had no issues with weight gain, depression, anxiety, or concentration at a dose of 10 mg at night.

5

Patient Review

1/10/2009

Zyprexa Zydis for Mental Disorder with Loss of Normal Personality & Reality

I am so pleased with this medication. I only wish I had started taking it sooner.

5

Patient Review

12/2/2008

Zyprexa Zydis for Bipolar Disorder in Remission

If you've gained weight, get active and go to the gym or something! Zyprexa has always worked for me and I haven't had any issues for years now.

3.7

Patient Review

10/2/2009

Zyprexa Zydis for Mental Disorder with Loss of Normal Personality & Reality

I am a 240 pound, 5'5" male with high cholesterol and triglycerides.

3.3

Patient Review

4/13/2009

Zyprexa Zydis for Schizophrenia

Worked great at first, but then the effects petered out after a few months. I still experienced some side effects even after it stopped being effective which were mostly increased appetite and fatigue. Your experience may be different, but mine was not good.

3

Patient Review

11/6/2007

Zyprexa Zydis for Bipolar I Disorder with Most Recent Episode Mixed

I find that if I don't take this medication, I feel more anxious; however, it doesn't seem to do much else. The downside is that I've experienced severe weight gain as a result of taking it.

3

Patient Review

4/23/2012

Zyprexa Zydis for Bipolar I Disorder with Most Recent Episode Mixed

This medication was successful in curbing her manic episodes of anxiety and anger. However, once it hit her system she became incredibly depressed and would cry for hours on end. We haven't decided if we will continue using it yet.

3

Patient Review

8/25/2011

Zyprexa Zydis for Schizophrenia

My weight has been more unstable since I began taking this medication.

2.7

Patient Review

12/28/2007

Zyprexa Zydis for Additional Medications to Treat Depression

I've found that my symptoms have actually gotten worse since starting this medication, and I've also gained weight.

1

Patient Review

11/10/2009

Zyprexa Zydis for Manic-Depression

I haven't tried it yet.

1

Patient Review

5/25/2014

Zyprexa Zydis for Bipolar I Disorder with Most Recent Episode Mixed

I gained a ton of weight in just three weeks from using this. Please, look for something else!
image of drug pills surrounding a glass of water symbolizing drug consumption

Patient Q&A Section about zyprexa zydis

These questions and answers are submitted by anonymous patients, and have not been verified by our internal team.

Is Zyprexa and Zyprexa Zydis the same thing?

"Zyprexa Zydis wafers are just as effective as Zyprexa coated tablets, with a similar rate and extent of absorption. Zyprexa Zydis wafers have the same dosage and frequency of administration as Zyprexa coated tablets. Zyprexa Zydis wafers may be used as an alternative to Zyprexa coated tablets."

Answered by AI

How long does it take for Zyprexa Zydis to dissolve?

"For treating bipolar disorder on a long-term basis, the recommended dose of olanzapine is 5-20 mg per day. The orally disintegrating tablet form of olanzapine is placed in your mouth, where it will dissolve within a few seconds."

Answered by AI

How do you administer Zyprexa Zydis?

"To take ZYPREXA ZYDIS (olanzapine orally disintegrating tablets), open the sachet and peel back the foil on the blister. Do not push the tablet through the foil. Using dry hands, remove the tablet from the blister and place the entire tablet in your mouth."

Answered by AI

What is Zyprexa Zydis used for?

"Olanzapine belongs to a class of drugs called atypical antipsychotics.

Olanzapine is a drug used to treat mental and mood conditions such as schizophrenia and bipolar disorder. It may also be used to treat depression in combination with other medications. Olanzapine belongs to a class of drugs called atypical antipsychotics."

Answered by AI

Clinical Trials for Zyprexa Zydis

Image of Columbia University Irving Medical Center in New York, United States.

Mindfulness-Based Exposure Therapy for PTSD After Cardiac Arrest

18 - 81
All Sexes
New York, NY

The goal of this clinical trial is to learn if a new therapy called Acceptance- and Mindfulness-Based Exposure Therapy (AMBET) helps treat post-traumatic stress disorder (PTSD) in people who survived a cardiac arrest. This study will compare AMBET to another psychotherapy treatment called Present Centered Therapy (PCT) to see which therapy is more effective in treating PTSD. The main questions it aims to answer are: Does AMBET reduce PTSD symptoms in survivors of cardiac arrest? How do the benefits of AMBET compare to PCT? Participants will: * Be randomly assigned to receive either AMBET or PCT * Attend 12 hours of individual psychotherapy sessions over about 12 weeks * Complete short weekly surveys about their mood and behaviors online * Wear a Fitbit device to track sleep and activity during the study * Do brief homework assignments between sessions

Waitlist Available
Has No Placebo

Columbia University Irving Medical Center

Yuval Neria, PhD

Image of The University of Texas Health Science Center at Houston in Houston, United States.

Cognitive Behavioral Therapy for Post-Traumatic Stress Disorder

7 - 14
All Sexes
Houston, TX

One of the most common and widely disseminated trauma treatments is Trauma Focused Cognitive Behavioral Therapy (TF-CBT). TF-CBT is a therapist-led, structured and sequential intervention, with treatment organized around P.R.A.C.T.I.C.E. (Psychoeducation, Parent training, Relaxation, Affective Regulation, Cognitive Coping, Trauma Narrative, In-Vivo Exposure, Cognitive Reprocessing, and Enhancing Safety) components. Stepped Care Cognitive Behavioral Therapy for Children after Trauma (SC-CBT-CT) is an alternative delivery system that incorporates the best available evidence on the treatment of childhood Post-traumatic Stress Disorder (PTSD) within a stepped care model and utilizes task-shifting with caregiver involvement, which engages caregivers in actively helping their children. Stepped care approaches are characterized by a personalized approach to care in which a lower intensity (i.e., fewer number of sessions) intervention is initially provided before the child is reevaluated or ''stepped up'' for additional care should symptoms persist. The goal of this study is to assess a personalized modification of SC-CBT-CT for Latino families (pSC-CBT-CT). The hypothesis is that personalizing SC-CBT-CT will improve outcomes for Latino children.

Waitlist Available
Has No Placebo

The University of Texas Health Science Center at Houston

Leslie K Taylor, PhD

Image of The University of Texas Health Science Center at Houston in Houston, United States.

Personalized Cognitive Behavioral Therapy for Post-Traumatic Stress Disorder

7 - 14
All Sexes
Houston, TX

One of the most common and widely disseminated trauma treatments is Trauma Focused Cognitive Behavioral Therapy (TF-CBT). TF-CBT is a therapist-led, structured and sequential intervention, with treatment organized around P.R.A.C.T.I.C.E. (Psychoeducation, Parent training, Relaxation, Affective Regulation, Cognitive Coping, Trauma Narrative, In-Vivo Exposure, Cognitive Reprocessing, and Enhancing Safety) components. Stepped Care Cognitive Behavioral Therapy for Children after Trauma (SC-CBT-CT) is an alternative delivery system that incorporates the best available evidence on the treatment of childhood Post-traumatic Stress Disorder (PTSD) within a stepped care model and utilizes task-shifting with caregiver involvement, which engages caregivers in actively helping their children. Stepped care approaches are characterized by a personalized approach to care in which a lower intensity (i.e., fewer number of sessions) intervention is initially provided before the child is reevaluated or ''stepped up'' for additional care should symptoms persist. The goal of this study is to assess a personalized modification of SC-CBT-CT for Latino families (pSC-CBT-CT). The hypothesis is that personalizing SC-CBT-CT will improve outcomes for Latino children.

Waitlist Available
Has No Placebo

The University of Texas Health Science Center at Houston

Leslie K Taylor, PhD

Have you considered Zyprexa Zydis clinical trials?

We made a collection of clinical trials featuring Zyprexa Zydis, we think they might fit your search criteria.
Go to Trials
Image of Sunnybrook Health Sciences Centre in Toronto, Canada.

Ketogenic Diet and Neuromodulation for Depression

18 - 65
All Sexes
Toronto, Canada

The goal of this clinical trial is to test whether combining a ketogenic diet (KD) with personalized, accelerated intermittent theta burst stimulation (iTBS) produces greater reductions in depressive symptoms than iTBS combined with a standard healthy diet in adults with treatment-resistant depression. The trial also aims to determine whether participants can feasibly follow a ketogenic diet during an accelerated iTBS treatment course and whether the diet produces measurable changes in ketone levels. Specifically, the study aims to determine whether the combined intervention: 1. Reduces depressive symptoms 2. Increases circulating ketone levels 3. Is feasible and tolerable during accelerated iTBS treatment Participants will begin either a KD or a Canadian Food Guide-aligned diet (CFGD) with a 3-week dietary lead-in period, after which they will undergo a course of personalized, accelerated iTBS while continuing their assigned diet. Before and after the iTBS treatment course, participants will complete clinical assessments, provide blood samples for metabolic testing, and undergo MRI scans to assess brain connectivity. Ketone levels will be measured daily throughout the 12-week dietary intervention. Within-group and between-group differences will be compared to characterize changes in clinical outcomes, metabolism, and brain functioning.

Waitlist Available
Has No Placebo

Sunnybrook Health Sciences Centre

Have you considered Zyprexa Zydis clinical trials?

We made a collection of clinical trials featuring Zyprexa Zydis, we think they might fit your search criteria.
Go to Trials
Image of Stanford University School of Medicine in Stanford, United States.

BEAR Program for Suicidal Thoughts

18 - 75
Female
Stanford, CA

The current study aims to test the feasibility of a new form of group therapy for women who have a history of interpersonal trauma and current suicidal ideation. The Building Empowerment and Resilience (BEAR) Therapeutic group has been adapted for women who have experienced trauma and have current suicidal ideation. It incorporates psychological skills, psychoeducation about trauma and gender-based violence, and physical self-defense training, all within a therapeutic process. It will be implemented with women who have experienced interpersonal trauma (physical, sexual, or emotional abuse/neglect) and experience various mental health difficulties, including suicidal ideation. We aim to assess the feasibility to recruit and implement the BEAR group. Our ultimate aim is to assess whether the program can effect self-efficacy and suicidal ideation.

Waitlist Available
Has No Placebo

Stanford University School of Medicine

Jennifer Keller, PhD

Image of White River Junction VA Hospital in White River Junction, United States.

Transcranial Magnetic Stimulation for PTSD

19 - 70
All Sexes
White River Junction, VT

With this research investigators hope to begin to understand how rTMS can improve posttraumatic stress disorder (PTSD) symptoms. TMS improves PTSD through two interrelated mechanisms: change in brain limbic system function and change in systemic inflammatory activation. Participants who decide to join this study, will receive ten rTMS treatments. All participants will undergo a 40-minute rTMS procedure with a member of the study team 10 times over 2-4 weeks. Participants will undergo fMRI scans of the head in order to help researchers better understand potential effects of rTMS on brain activity. In addition, participants will be asked to give two breath and blood samples to look for signs of general inflammation.

Recruiting
Has No Placebo

White River Junction VA Hospital

Bradley Watts

Have you considered Zyprexa Zydis clinical trials?

We made a collection of clinical trials featuring Zyprexa Zydis, we think they might fit your search criteria.
Go to Trials